Cargando…
A New Therapeutic Candidate for Cardiovascular Diseases: Berberine
Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) ha...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010184/ https://www.ncbi.nlm.nih.gov/pubmed/33815112 http://dx.doi.org/10.3389/fphar.2021.631100 |
_version_ | 1783673010725584896 |
---|---|
author | Cai, Yun Xin, Qiqi Lu, Jinjin Miao, Yu Lin, Qian Cong, Weihong Chen, Keji |
author_facet | Cai, Yun Xin, Qiqi Lu, Jinjin Miao, Yu Lin, Qian Cong, Weihong Chen, Keji |
author_sort | Cai, Yun |
collection | PubMed |
description | Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD. |
format | Online Article Text |
id | pubmed-8010184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80101842021-04-01 A New Therapeutic Candidate for Cardiovascular Diseases: Berberine Cai, Yun Xin, Qiqi Lu, Jinjin Miao, Yu Lin, Qian Cong, Weihong Chen, Keji Front Pharmacol Pharmacology Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD. Frontiers Media S.A. 2021-03-17 /pmc/articles/PMC8010184/ /pubmed/33815112 http://dx.doi.org/10.3389/fphar.2021.631100 Text en Copyright © 2021 Cai, Xin, Lu, Miao, Lin, Cong and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Cai, Yun Xin, Qiqi Lu, Jinjin Miao, Yu Lin, Qian Cong, Weihong Chen, Keji A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title | A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title_full | A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title_fullStr | A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title_full_unstemmed | A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title_short | A New Therapeutic Candidate for Cardiovascular Diseases: Berberine |
title_sort | new therapeutic candidate for cardiovascular diseases: berberine |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010184/ https://www.ncbi.nlm.nih.gov/pubmed/33815112 http://dx.doi.org/10.3389/fphar.2021.631100 |
work_keys_str_mv | AT caiyun anewtherapeuticcandidateforcardiovasculardiseasesberberine AT xinqiqi anewtherapeuticcandidateforcardiovasculardiseasesberberine AT lujinjin anewtherapeuticcandidateforcardiovasculardiseasesberberine AT miaoyu anewtherapeuticcandidateforcardiovasculardiseasesberberine AT linqian anewtherapeuticcandidateforcardiovasculardiseasesberberine AT congweihong anewtherapeuticcandidateforcardiovasculardiseasesberberine AT chenkeji anewtherapeuticcandidateforcardiovasculardiseasesberberine AT caiyun newtherapeuticcandidateforcardiovasculardiseasesberberine AT xinqiqi newtherapeuticcandidateforcardiovasculardiseasesberberine AT lujinjin newtherapeuticcandidateforcardiovasculardiseasesberberine AT miaoyu newtherapeuticcandidateforcardiovasculardiseasesberberine AT linqian newtherapeuticcandidateforcardiovasculardiseasesberberine AT congweihong newtherapeuticcandidateforcardiovasculardiseasesberberine AT chenkeji newtherapeuticcandidateforcardiovasculardiseasesberberine |